Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer
Authors:
Open Access
Abstract
Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult oncologic treatment protocols. The main platinum compounds are cisplatin, carboplatin, and oxaliplatin. Their use in clinical practice has greatly improved long-term survival of pediatric patients, but they also cause some toxic effects: ototoxicity, myelosuppression, nephrotoxicity, and neurotoxicity. Hearing damage is one of the main toxic effects of platinum compounds, and it derives from the degeneration of hair cells of the ear, which, not having self-renewal capacity, cannot reconstitute themselves. Hearing loss from platinum exposure is typically bilateral, sensorineural, and permanent, and it is caused by the same mechanisms with which platinum acts on neoplastic cells. According to available data from the literature, the optimal timing for the audiological test during and after treatment with platinum compounds is not well defined. Moreover, no substances capable of preventing the onset of hearing loss have been identified.Keywords
This publication has 87 references indexed in Scilit:
- Clinical Practice GuidelineOtolaryngology–Head and Neck Surgery, 2012
- Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology GroupPediatrics, 2010
- Amifostine does not prevent platinum‐induced hearing loss associated with the treatment of children with hepatoblastomaCancer, 2009
- Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk MedulloblastomaJournal of Clinical Oncology, 2008
- Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumoursBritish Journal of Cancer, 2007
- Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer SurvivorsJournal of Clinical Oncology, 2007
- Effect of population and gender on chemotherapeutic agent–induced cytotoxicityMolecular Cancer Therapeutics, 2007
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseEuropean Journal of Cancer, 2004
- Protective effects of α-tocopherol and tiopronin against cisplatin-induced ototoxicityActa Oto-Laryngologica, 2004
- Clinical Pharmacokinetics and Administration of Established Platinum DrugsDrugs, 2000